| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Over the last 12 months, insiders at GlucoTrack, Inc. have bought $0 and sold $0 worth of GlucoTrack, Inc. stock.
On average, over the past 5 years, insiders at GlucoTrack, Inc. have bought $230,000 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 182,540 shares for transaction amount of $230,000 was made by SYCOFF DREW () on 2024‑04‑22.
| Increased Positions | 4 | +44.44% | 59,455 | +944.03% |
| Decreased Positions | 3 | -33.33% | 1,781 | -28.28% |
| New Positions | 2 | New | 59,355 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 10 | +11.11% | 63,972 | +915.75% |